Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma

News
Article

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.

“I think what we show here is that this is a safe place to do a surgery, after the checkpoint inhibitors. We had a couple of complications, but none of these were surgical complications in this cohort of patients,” according to Jason Scovell, MD, PhD.

“I think what we show here is that this is a safe place to do a surgery, after the checkpoint inhibitors. We had a couple of complications, but none of these were surgical complications in this cohort of patients,” according to Jason Scovell, MD, PhD.

Treatment with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) followed by surgery demonstrated safety among those with locally advanced renal cell carcinoma (RCC), according to findings presented during the 2023 Society of Urologic Oncology (SUO) Annual Meeting.

Explaining the rational for the study, Jason Scovell, MD, PhD, Glickman Urologic and Kidney Institute, Cleveland Clinic, said, “We don’t really know what the immune checkpoint inhibitors are doing to the anatomy of the kidney prior to the surgery, and the surgical safety and efficacy for partial and radical therapy for patients with complex locally advanced renal tumors is not well established.”

Accordingly, the single-arm open-label phase 1b study included 25 patients with locally advanced RCC (stage T2b-4 and/or N1, M0 disease) enrolled at the Cleveland Clinic Foundation or the University of Minnesota between 2016 and 2020. At baseline, the median patient age was 61 years (range, 52-65) and the median BMI was 29 (range, 25-32). All 25 patients were White, 8 patients were former smokers, and 17 patients were never-smokers.

The median Charlson Comorbidity was 4 (range, 3-5) and all patients had an ECOG performance status of 0. Twenty-three patients had clinical stage III disease and 2 patients had stage II disease. The pathologic stage was stage I for 1 patient, stage II for 3 patients, stage III for 20 patients, and stage IV for 1 patient. The histology was as follows: chromophobe (n = 1), clear cell (n = 21), papillary (n = 1), HLRCC (n = 1), and unclassified (n = 1). Histologic features comprised 2 patients with rhabdoid, 4 patients with sarcomatoid, and 16 patients with necrosis.

The study design was for patients to receive neoadjuvant therapy followed by nephrectomy, and then adjuvant therapy 4 to 6 weeks after surgery. The investigators evaluated 4 treatment cohorts. In the neoadjuvant setting patients in cohort 1 received 1 dose of durvalumab and patients in cohorts 2, 2a, and 3 received 1 dose of durvalumab plus tremelimumab.

In the adjuvant setting, patients in cohort 1 and cohort 2 received 1 dose of durvalumab. Patients in cohort 2a received adjuvant durvalumab for 1 year, and patients in cohort 3 received 1 dose of durvalumab/tremelimumab following by single-agent durvalumab for 1 year.

Overall, 23 patients received both neoadjuvant and adjuvant therapy and 2 patients received only neoadjuvant therapy.

Tumors were considered to be surgically complex with over half of patients having a RENAL score of 11xh.

The majority of patients received radical nephrectomy (n = 23), with patients undergoing both minimally invasive (n = 8) and open (n = 17) procedures. Six of the patients’ tumors had renal vein involvement. There were no reported intraoperative complications. The median estimated blood loss was 375 cc (interquartile range [IQR], 188-775). Three patients received a blood transfusion after surgery.

There were no intraoperative complications. Five patients had positive margins, which were all located at the renal vein wall. Patients were in the hospital for a median stay of 4 days (IQR, 3-5), with readmission required for 3 patients for diabetic ketoacidosis, thrombocytopenia, and pulmonary embolism. Five 30-day and 90-day Clavien complications occurred.

“I think what we show here is that this is a safe place to do a surgery, after the checkpoint inhibitors. We had a couple of complications, but none of these were surgical complications in this cohort of patients,” said Scovell.

Regarding next steps, Scovell, said, “There’s a lot of molecular work that’s being done on the tissue as part of this trial.”

Reference

Zabell J, Rini BI, Krishnamurthi V, et al. Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab). Presented at: 2023 Society of Urologic Oncology Annual Meeting. November 28 – December 1, 2023; Washington, DC. Abstract 7.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content